Tscan Cost Of Revenue vs Other Operating Expenses Analysis

TCRX Stock

USD 4.52 0.26 6.10%

Tscan Therapeutics financial indicator trend analysis is much more than just breaking down Tscan Therapeutics prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tscan Therapeutics is a good investment. Please check the relationship between Tscan Therapeutics Cost Of Revenue and its Other Operating Expenses accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tscan Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.

Cost Of Revenue vs Other Operating Expenses

Cost Of Revenue vs Other Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tscan Therapeutics Cost Of Revenue account and Other Operating Expenses. At this time, the significance of the direction appears to have strong relationship.

The correlation between Tscan Therapeutics' Cost Of Revenue and Other Operating Expenses is 0.74. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Other Operating Expenses in the same time period over historical financial statements of Tscan Therapeutics, assuming nothing else is changed. The correlation between historical values of Tscan Therapeutics' Cost Of Revenue and Other Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Tscan Therapeutics are associated (or correlated) with its Other Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Operating Expenses has no effect on the direction of Cost Of Revenue i.e., Tscan Therapeutics' Cost Of Revenue and Other Operating Expenses go up and down completely randomly.

Correlation Coefficient

0.74

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Tscan Therapeutics income statement and represents the costs associated with goods and services Tscan Therapeutics provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Tscan Therapeutics. It is also known as Tscan Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Most indicators from Tscan Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tscan Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tscan Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Tscan Stock please use our How to Invest in Tscan Therapeutics guide.At this time, Tscan Therapeutics' Issuance Of Capital Stock is fairly stable compared to the past year. Enterprise Value is likely to rise to about 358.6 M in 2024, whereas Selling General Administrative is likely to drop slightly above 15.8 M in 2024.

	2021	2022	2023	2024 (projected)
Interest Income	17K	1.6M	6.3M	6.6M
Net Interest Income	16K	415K	2.4M	2.5M

Interest Income Net Interest Income

Tscan Therapeutics fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Capital Lease Obligations	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.84	0.94	0.91	0.96	0.92	0.91	0.71	-0.39	-0.92	0.69	0.94	0.92	1.0	0.99	0.98	-0.8	0.71	0.07	0.84	0.7	0.96	0.47	0.95	0.72	0.98
Short Long Term Debt Total	0.84		0.75	0.75	0.69	0.72	0.93	0.5	0.08	-0.96	0.73	0.68	0.93	0.8	0.79	0.75	-0.71	0.67	0.47	1.0	0.38	0.7	0.75	0.84	0.83	0.74
Other Current Liab	0.94	0.75		0.99	0.9	0.86	0.82	0.89	-0.42	-0.89	0.77	0.88	0.82	0.95	0.92	0.95	-0.89	0.75	0.04	0.76	0.69	0.94	0.48	0.89	0.76	0.95
Total Current Liabilities	0.91	0.75	0.99		0.85	0.82	0.81	0.93	-0.38	-0.88	0.86	0.85	0.82	0.91	0.89	0.9	-0.95	0.67	0.06	0.76	0.7	0.92	0.51	0.85	0.73	0.9
Total Stockholder Equity	0.96	0.69	0.9	0.85		0.98	0.78	0.7	-0.62	-0.82	0.57	0.99	0.79	0.98	0.97	0.99	-0.75	0.57	-0.2	0.69	0.83	0.98	0.21	0.95	0.6	0.99
Net Tangible Assets	0.92	0.72	0.86	0.82	0.98		0.74	0.7	-0.63	-0.84	0.59	0.99	0.76	0.95	0.93	0.95	-0.76	0.48	-0.25	0.72	0.87	0.97	0.16	0.98	0.63	0.95
Property Plant And Equipment Net	0.91	0.93	0.82	0.81	0.78	0.74		0.54	-0.01	-0.9	0.77	0.75	1.0	0.88	0.9	0.82	-0.75	0.68	0.43	0.93	0.44	0.78	0.74	0.81	0.67	0.81
Current Deferred Revenue	0.71	0.5	0.89	0.93	0.7	0.7	0.54		-0.51	-0.69	0.8	0.73	0.55	0.75	0.7	0.75	-0.93	0.49	-0.16	0.51	0.73	0.82	0.28	0.7	0.6	0.75
Net Debt	-0.39	0.08	-0.42	-0.38	-0.62	-0.63	-0.01	-0.51		0.14	-0.07	-0.66	-0.05	-0.47	-0.45	-0.53	0.35	0.06	0.89	0.08	-0.85	-0.62	0.59	-0.47	0.0	-0.54
Retained Earnings	-0.92	-0.96	-0.89	-0.88	-0.82	-0.84	-0.9	-0.69	0.14		-0.75	-0.8	-0.9	-0.9	-0.87	-0.88	0.81	-0.75	-0.28	-0.96	-0.54	-0.84	-0.64	-0.93	-0.9	-0.87
Accounts Payable	0.69	0.73	0.77	0.86	0.57	0.59	0.77	0.8	-0.07	-0.75		0.61	0.78	0.69	0.71	0.61	-0.95	0.39	0.28	0.74	0.54	0.68	0.63	0.64	0.54	0.61
Cash	0.94	0.68	0.88	0.85	0.99	0.99	0.75	0.73	-0.66	-0.8	0.61		0.77	0.97	0.96	0.97	-0.78	0.49	-0.26	0.68	0.89	0.99	0.16	0.95	0.57	0.97
Non Current Assets Total	0.92	0.93	0.82	0.82	0.79	0.76	1.0	0.55	-0.05	-0.9	0.78	0.77		0.89	0.91	0.83	-0.76	0.66	0.4	0.93	0.48	0.8	0.71	0.83	0.66	0.82
Non Currrent Assets Other	1.0	0.8	0.95	0.91	0.98	0.95	0.88	0.75	-0.47	-0.9	0.69	0.97	0.89		0.99	0.99	-0.82	0.66	-0.01	0.8	0.76	0.98	0.4	0.96	0.69	0.99
Other Assets	0.99	0.79	0.92	0.89	0.97	0.93	0.9	0.7	-0.45	-0.87	0.71	0.96	0.91	0.99		0.97	-0.81	0.61	0.01	0.79	0.75	0.96	0.41	0.93	0.61	0.97
Cash And Short Term Investments	0.98	0.75	0.95	0.9	0.99	0.95	0.82	0.75	-0.53	-0.88	0.61	0.97	0.83	0.99	0.97		-0.77	0.69	-0.09	0.75	0.76	0.98	0.33	0.96	0.7	1.0
Common Stock Total Equity	-0.8	-0.71	-0.89	-0.95	-0.75	-0.76	-0.75	-0.93	0.35	0.81	-0.95	-0.78	-0.76	-0.82	-0.81	-0.77		-0.45	-0.03	-0.71	-0.74	-0.85	-0.46	-0.78	-0.61	-0.78
Common Stock Shares Outstanding	0.71	0.67	0.75	0.67	0.57	0.48	0.68	0.49	0.06	-0.75	0.39	0.49	0.66	0.66	0.61	0.69	-0.45		0.44	0.68	0.09	0.57	0.69	0.6	0.83	0.69
Non Current Liabilities Total	0.07	0.47	0.04	0.06	-0.2	-0.25	0.43	-0.16	0.89	-0.28	0.28	-0.26	0.4	-0.01	0.01	-0.09	-0.03	0.44		0.47	-0.58	-0.19	0.89	-0.07	0.34	-0.1
Capital Lease Obligations	0.84	1.0	0.76	0.76	0.69	0.72	0.93	0.51	0.08	-0.96	0.74	0.68	0.93	0.8	0.79	0.75	-0.71	0.68	0.47		0.38	0.7	0.75	0.84	0.84	0.74
Other Current Assets	0.7	0.38	0.69	0.7	0.83	0.87	0.44	0.73	-0.85	-0.54	0.54	0.89	0.48	0.76	0.75	0.76	-0.74	0.09	-0.58	0.38		0.86	-0.18	0.77	0.28	0.76
Other Stockholder Equity	0.96	0.7	0.94	0.92	0.98	0.97	0.78	0.82	-0.62	-0.84	0.68	0.99	0.8	0.98	0.96	0.98	-0.85	0.57	-0.19	0.7	0.86		0.25	0.94	0.62	0.98
Total Liab	0.47	0.75	0.48	0.51	0.21	0.16	0.74	0.28	0.59	-0.64	0.63	0.16	0.71	0.4	0.41	0.33	-0.46	0.69	0.89	0.75	-0.18	0.25		0.33	0.62	0.32
Net Invested Capital	0.95	0.84	0.89	0.85	0.95	0.98	0.81	0.7	-0.47	-0.93	0.64	0.95	0.83	0.96	0.93	0.96	-0.78	0.6	-0.07	0.84	0.77	0.94	0.33		0.77	0.95
Property Plant And Equipment Gross	0.72	0.83	0.76	0.73	0.6	0.63	0.67	0.6	0.0	-0.9	0.54	0.57	0.66	0.69	0.61	0.7	-0.61	0.83	0.34	0.84	0.28	0.62	0.62	0.77		0.7
Total Current Assets	0.98	0.74	0.95	0.9	0.99	0.95	0.81	0.75	-0.54	-0.87	0.61	0.97	0.82	0.99	0.97	1.0	-0.78	0.69	-0.1	0.74	0.76	0.98	0.32	0.95	0.7

Click cells to compare fundamentals

Tscan Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Tscan Stock Analysis

When running Tscan Therapeutics' price analysis, check to measure Tscan Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tscan Therapeutics is operating at the current time. Most of Tscan Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tscan Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tscan Therapeutics' price. Additionally, you may evaluate how the addition of Tscan Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tscan Cost Of Revenue vs Other Operating Expenses Analysis

Cost Of Revenue vs Other Operating Expenses

Cost Of Revenue vs Other Operating Expenses Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Other Operating Expenses

Tscan Therapeutics fundamental ratios Correlations

Tscan Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Tscan Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Non Currrent Assets Other	+ 1.0	Total Assets
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Total Current Assets	+ 1.0	Cash And Short Term Investments
Other Assets	+ 0.99	Total Assets
Total Current Liabilities	+ 0.99	Other Current Liab

Capital Lease Obligations	- 0.96	Retained Earnings
Retained Earnings	- 0.96	Short Long Term Debt Total
Common Stock Total Equity	- 0.95	Accounts Payable
Common Stock Total Equity	- 0.95	Total Current Liabilities
Net Invested Capital	- 0.93	Retained Earnings
Common Stock Total Equity	- 0.93	Current Deferred Revenue